Pischon Tobias, Nimptsch Katharina
Molecular Epidemiology Research Group, Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Robert-Rössle-Straße 10, 13125, Berlin, Germany.
Recent Results Cancer Res. 2016;208:1-15. doi: 10.1007/978-3-319-42542-9_1.
The prevalence of obesity has increased substantially in the past in almost all countries of the world, and a further increase is expected for the future. Besides the well-established effects on type 2 diabetes and cardiovascular disease, there is convincing evidence today that obesity also increases the risk of several types of cancer, including colorectal cancer, postmenopausal breast cancer, endometrial cancer, renal cell carcinoma, esophageal adenocarcinoma, pancreatic cancer, and liver cancer. Obesity probably also increases the risk of ovarian cancer, advanced prostate cancer, gallbladder cancer, and gastric cardia cancer. For some cancer types, there is also some evidence that weight gain during adulthood increases cancer risk, e.g., colorectal cancer, postmenopausal breast cancer, endometrial cancer, and liver cancer. However, for most cancers, it is an open question as to whether vulnerability to weight gain in relation to cancer risk depends on specific life periods. There are a number of plausible mechanisms that may explain the relationship between obesity and cancer risk, including pathways related to insulin resistance, inflammation, and sex hormones. For most cancers, there is only limited evidence that weight loss in adulthood decreases cancer risk, which is primarily due to the limited long-term success of weight loss strategies among obese individuals. There is limited evidence suggesting that obesity may also be associated with poor prognosis among patients with colorectal cancer, breast cancer, endometrial cancer, ovarian cancer, and pancreatic cancer. Taken together, these findings support efforts to prevent weight gain on an individual level as well as on a population level. Whether and to what extent overweight or obese cancer patients benefit from weight loss strategies is unclear and needs to be addressed in future studies.
在过去,全球几乎所有国家肥胖症的患病率都大幅上升,预计未来还会进一步增加。除了对2型糖尿病和心血管疾病已明确的影响外,如今有令人信服的证据表明,肥胖还会增加多种癌症的风险,包括结直肠癌、绝经后乳腺癌、子宫内膜癌、肾细胞癌、食管腺癌、胰腺癌和肝癌。肥胖可能还会增加卵巢癌、晚期前列腺癌、胆囊癌和贲门癌的风险。对于某些癌症类型,也有证据表明成年期体重增加会增加癌症风险,例如结直肠癌、绝经后乳腺癌、子宫内膜癌和肝癌。然而,对于大多数癌症而言,与癌症风险相关的体重增加易感性是否取决于特定的生命阶段仍是一个悬而未决的问题。有许多合理的机制可以解释肥胖与癌症风险之间的关系,包括与胰岛素抵抗、炎症和性激素相关的途径。对于大多数癌症,仅有有限的证据表明成年期体重减轻会降低癌症风险,这主要是由于肥胖个体体重减轻策略的长期成功率有限。有有限的证据表明,肥胖也可能与结直肠癌、乳腺癌、子宫内膜癌、卵巢癌和胰腺癌患者的预后不良有关。综上所述,这些发现支持在个体层面和人群层面预防体重增加的努力。超重或肥胖的癌症患者是否以及在多大程度上能从体重减轻策略中获益尚不清楚,需要在未来的研究中加以解决。